Epigenetic modifications in prostate cancer

Epigenomics

Volumn 6, Issue 4, 2014, Pages 415-426

  Ngollo, Marjolaine ^a,b   Dagdemir, Aslihan ^a,b   Karsli Ceppioglu, Seher ^a,c   Judes, Gaelle ^a,b   Pajon, Amaury ^a,b   Penault Llorca, Frederique ^a,b   Boiteux, Jean Paul ^d   Bignon, Yves Jean ^a,b   Guy, Laurent ^b,d   Bernard Gallon, Dominique J ^a,b  

^a CENTRE JEAN PERRIN   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c MARMARA UNIVERSITY   (Turkey)

^d SERVICE DE RHUMATOLOGIE   (France)

Author keywords

DNA methylation; epigenetic modifications; histone methylation; microRNA; prostate cancer

Indexed keywords

DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HISTONE METHYLTRANSFERASE INHIBITOR; MICRORNA; UNCLASSIFIED DRUG; HISTONE; HISTONE LYSINE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE;

DEACETYLATION; DNA FRAGMENTATION; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; MEDICAL RESEARCH; PROSTATE CANCER; REVIEW; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; ANTAGONISTS AND INHIBITORS; GENETIC EPIGENESIS; GENETICS; MALE; METABOLISM; PROSTATIC NEOPLASMS;

DNA METHYLATION; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS;

EID: 84908156914     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.34     Document Type: Review

References (89)

1. Chin SP, Dickinson JL, Holloway AF. Epigenetic regulation of prostate cancer. Clin. Epigenetics 2(2), 151-169 (2011).
2. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447(7143), 425-432 (2007).
3. Jurkowska RZ, Jurkowski TP, Jeltsch A. Structure and function of mammalian DNA methyltransferases. Chembiochem 12(2), 206-222 (2011).
4. Gravina GL, Ranieri G, Muzi P et al. Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells. Oncol. Rep. 29(3), 1189-1195 (2013).
5. Ehrlich M. Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr. Top. Microbiol. Immunol. 310, 251-274 (2006).
6. Watanabe Y, Maekawa M. Methylation of DNA in cancer. Adv. Clin. Chem. 52, 145-167 (2010).
7. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim. Biophys. Acta 1775(1), 138-162 (2007).
8. Yu YP, Ding Y, Chen R et al. Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer. Am. J. Pathol. 183(6), 1960-1970 (2013).
9. Vardi A, Bosviel R, Rabiau N et al. Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells. In vivo 24(4), 393-400 (2010).
10. Rabiau N, Thiam MO, Satih S et al. Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy. In vivo 23(3), 387-391 (2009).
11. Adjakly M, Bosviel R, Rabiau N et al. DNA methylation and soy phytoestrogens: quantitative study in DU-145 and PC-3 human prostate cancer cell lines. Epigenomics 3(6), 795-803 (2011).
12. Yoon H-Y, Kim S-K, Kim Y-W et al. Combined hypermethylation of APC and GSTP1 as a molecular marker for prostate cancer: quantitative pyrosequencing analysis. J. Biomol. Screen. 17(7), 987-992 (2012).
13. Dumitrescu RG. Epigenetic markers of early tumor development. Methods Mol. Biol. 863, 3-14 (2012).
14. Yegnasubramanian S, Kowalski J, Gonzalgo ML et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 64(6), 1975-1986 (2004).
15. Liu L, Yoon J-H, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 21(44), 6835-6840 (2002).
16. Cho N-Y, Kim JH, Moon KC, Kang GH. Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch. 454(1), 17-23 (2009).
17. Li D, Kumaraswamy E, Harlan-Williams LM, Jensen RA. The role of BRCA1 and BRCA2 in prostate cancer. Front. Biosci. (Landmark Edition) 18, 1445-1459 (2013).
18. Agarwal S, Amin KS, Jagadeesh S et al. Mahanine restores RASSF1A expression by down-regulating DNMT1 and DNMT3B in prostate cancer cells. Mol. Cancer 12(1), 99 (2013).
19. Zhang C, Su Z-Y, Khor TO, Shu L, Kong A-NT. Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation. Biochem. Pharmacol. 85(9), 1398-1404 (2013).
20. Wu G, Yi N, Absher D, Zhi D. Statistical quantification of methylation levels by next-generation sequencing. PloS ONE 6(6), e21034 (2011).
21. Yu YP, Ding Y, Chen R et al. Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer. Am. J. Pathol. 183(6), 1960-1970 (2013).
22. Chiam K, Centenera MM, Butler LM, Tilley WD, Bianco-Miotto T. GSTP1 DNA methylation and expression status is indicative of 5-aza-2-deoxycytidine efficacy in human prostate cancer cells. PloS ONE 6(9), e25634 (2011).
23. Kawamoto K, Okino ST, Place RF et al. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin. Cancer Res. 13(9), 2541-2548 (2007).
24. Loh YH, Mitrou PN, Bowman R et al. MGMT Ile143Val polymorphism, dietary factors and the risk of breast, colorectal and prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk study. DNA Repair (Amsterdam) 9(4), 421-428 (2010).
25. Wegiel B, Bjartell A, Tuomela J et al. Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis. J. Natl Cancer Inst. 100(14), 1022-1036 (2008).
26. Brett A, Pandey S, Fraizer G. The Wilms tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cells. Mol. Cancer 12, 3 (2013).
27. Fujii S, Ito K, Ito Y, Ochiai A. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J. Biol. Chem. 283(25), 17324-17332 (2008).
28. Daniels G, Gellert LL, Melamed J et al. Decreased expression of stromal estrogen receptor α and β in prostate cancer. Am. J. Transl. Res. 6(2), 140-146 (2014).
29. Ameri A, Alidoosti A, Hosseini SY et al. Prognostic value of promoter hypermethylation of retinoic acid receptor beta (RARB) and CDKN2 (p16/MTS1) in prostate cancer. Chin. J. Cancer Res. 23(4), 306-311 (2011).
30. Moison C, Senamaud-Beaufort C, Fourrire L et al. DNA methylation associated with polycomb repression in retinoic acid receptor β silencing. FASEB J. 27(4), 1468-1478 (2013).
31. Sullivan L, Murphy TM, Barrett C et al. IGFBP7 promoter methylation and gene expression analysis in prostate cancer. J. Urol. 188(4), 1354-1360 (2012).
32. Perry AS, OHurley G, Raheem OA et al. Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer. Int. J. Cancer 132(8), 1771-1780 (2013).
33. Bhaumik SR, Smith E, Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nat. Struct. Mol. Biol. 14(11), 1008-1016 (2007).
34. Dagdemir A, Durif J, Ngollo M, Bignon Y-J, Bernard-Gallon D. Histone lysine trimethylation or acetylation can be modulated by phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines. Epigenomics 5(1), 51-63 (2013).
35. Lachner M, Jenuwein T. The many faces of histone lysine methylation. Curr. Opin. Cell Biol. 14(3), 286-298 (2002).
36. Kirmizis A, Bartley SM, Kuzmichev A et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev. 18(13), 1592-1605 (2004).
37. Mller J, Hart CM, Francis NJ et al. Histone methyltransferase activity of a Drosophila polycomb group repressor complex. Cell 111(2), 197-208 (2002).
38. Li G, Margueron R, Ku M, Chambon P, Bernstein BE, Reinberg D. Jarid2 and PRC2, partners in regulating gene expression. Genes Dev. 24(4), 368-380 (2010).
39. Vir E, Brenner C, Deplus R et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439(7078), 871-874 (2006).
40. Karanikolas BDW, Figueiredo ML, Wu L. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol. Cancer Res. 7(9), 1456-1465 (2009).
41. Ngollo M, Dagdemir A, Judes G et al. Epigenetics of prostate cancer: distribution of histone H3K27me3 biomarkers in peri-tumoral tissue. OMICS 18(3), 207-209 (2014).
42. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22(20), 5323-5335 (2003).
43. Shiogama S, Yoshiba S, Soga D, Motohashi H, Shintani S. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration. Anticancer Res. 33(10), 4309-4317 (2013).
44. Ghosh AK, Steele R, Ray RB. MBP-1 physically associates with histone deacetylase for transcriptional repression. Biochem. Biophys. Res. Commun. 260(2), 405-409 (1999).
45. Au SL-K, Wong CC-L, Lee JM-F, Wong C-M, Ng IO-L. EZH2-mediated H3K27me3 is involved in epigenetic repression of deleted in liver cancer 1 in human cancers. PloS ONE 8(6), e68226 (2013).
46. Ke X-S, Qu Y, Rostad K et al. Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PloS ONE 4(3), e4687 (2009).
47. Chng KR, Chang CW, Tan SK et al. A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J. 31(12), 2810-2823 (2012).
48. Metzger E, Wissmann M, Yin N et al. LSD1 demethylates repressive histone marks to promote androgen-receptordependent transcription. Nature 437(7057), 436-439 (2005).
49. Cai C, He HH, Chen S et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 20(4), 457-471 (2011).
50. Wissmann M, Yin N, Mller JM et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat. Cell Biol. 9(3), 347-353 (2007).
51. Xiang Y, Zhu Z, Han G, Lin H, Xu L, Chen CD. JMJD3 is a histone H3K27 demethylase. Cell Res. 17(10), 850-857 (2007).
52. Agger K, Cloos PAC, Christensen J et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449(7163), 731-734 (2007).
53. Lu F, Li G, Cui X, Liu C, Wang X-J, Cao X. Comparative analysis of JmjC domain-containing proteins reveals the potential histone demethylases in Arabidopsis and rice. J. Integr. Plant Biol. 50(7), 886-896 (2008).
54. Coffey K, Rogerson L, Ryan-Munden C et al. The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover. Nucleic Acids Res. 41(8), 4433-4446 (2013).
55. Shi Y, Lan F, Matson C et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119(7), 941-953 (2004).
56. Shiau C, Trnka MJ, Bozicevic A et al. Reconstitution of nucleosome demethylation and catalytic properties of a jumonji histone demethylase. Chem. Biol. 20(4), 494-499 (2013).
57. Kouzarides T. Chromatin modifications and their function. Cell 128(4), 693-705 (2007).
58. Shilatifard A. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu. Rev. Biochem. 81, 65-95 (2012).
59. Cho Y-W, Hong T, Hong S et al. PTIP associates with MLL3-and MLL4-containing histone H3 lysine 4 methyltransferase complex. J. Biol. Chem. 282(28), 20395-20406 (2007).
60. Benson LJ, Phillips JA, Gu Y, Parthun MR, Hoffman CS, Annunziato AT. Properties of the type B histone acetyltransferase Hat1: H4 tail interaction, site preference, and involvement in DNA repair. J. Biol. Chem. 282(2), 836-842 (2007).
61. Gaughan L, Logan IR, Cook S, Neal DE, Robson CN. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J. Biol. Chem. 277(29), 25904-25913 (2002).
62. Culig Z, Santer FR. Androgen receptor co-activators in the regulation of cellular events in prostate cancer. World J. Urol. 30(3), 297-302 (2012).
63. Gong A-Y, Eischeid AN, Xiao J et al. miR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells. BMC Cancer 12(1), 492 (2012).
64. Fialova B, Smesny Trtkova K, Paskova L, Langova K, Kolar Z. Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines. Oncol. Rep. 29(5), 2039-2045 (2013).
65. Strunnikova M, Schagdarsurengin U, Kehlen A, Garbe JC, Stampfer MR, Dammann R. Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter. Mol. Cell. Biol. 25(10), 3923-3933 (2005).
66. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5(7), 522-531 (2004).
67. Wang N, Li Q, Feng N-H et al. miR-205 is frequently downregulated in prostate cancer and acts as a tumor suppressor by inhibiting tumor growth. Asian J. Androl. 15(6), 735-741 (2013).
68. Sun D, Layer R, Mueller AC et al. Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells. Oncogene 33(11), 1448-1457 (2014).
69. Friedman JM, Jones PA, Liang G. The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer. Cell Cycle Georget. Tex. 8(15), 2313-2314 (2009).
70. Schubert M, Spahn M, Kneitz S et al. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PloS One 8(6), e65064 (2013).
71. Formosa A, Lena AM, Markert EK et al. DNA methylation silences miR-132 in prostate cancer. Oncogene 32(1), 127-134 (2013).
72. Qu Y, Huang X, Li Z et al. New avenue for prostate cancer treatment: miR-199a-3p inhibits aurora kinase A and attenuates prostate cancer growth. Am. J. Pathol. 9440(14), 91 (2014).
73. Majid S, Dar AA, Saini S et al. miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin. Cancer Res. 19(1), 73-84 (2013).
74. Shen P-F, Chen X-Q, Liao Y-C et al. MicroRNA-494-3p targets CXCR4 to suppress the proliferation, invasion, and migration of prostate cancer. Prostate 74(6), 1-12 (2014).
75. Zhang W, Zang J, Jing X et al. Identification of candidate miRNA biomarkers from miRNA regulatory network with application to prostate cancer. J. Transl. Med. 12(1), 66 (2014).
76. Singh PK, Preus L, Hu Q et al. Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget 5(3), 824-840 (2014).
77. Noonan EJ, Place RF, Pookot D et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28(14), 1714-1724 (2009).
78. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 66(5), 2794-2800 (2006).
79. Graa I, Sousa E, Baptista T et al. Anti-tumoral effect of the non-nucleoside DNMT inhibitor RG108 in human prostate cancer cells. Curr. Pharm. Des. 19(1), 1-9 (2013).
80. Dong X, Xu W, Sikes RA, Wu C. Combination of low dose of genistein and daidzein has synergistic preventive effects on isogenic human prostate cancer cells when compared with individual soy isoflavone. Food Chem. 141(3), 1923-1933 (2013).
81. Roy S, Packman K, Jeffrey R, Tenniswood M. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ. 12(5), 482-491 (2005).
82. Paskova L, Trtkova KS, Fialova B, Benedikova A, Langova K, Kolar Z. Different effect of sodium butyrate on cancer and normal prostate cells. Toxicol. In vitro 27(5), 1489-1495 (2013).
83. Patra N, De U, Kim TH et al. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via upregulation of androgen receptor expression in human prostate cancer cells. Biomed. Pharmacother. 67(5), 407-415 (2013).
84. Laurenzana A, Balliu M, Cellai C, Romanelli MN, Paoletti F. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells. PloS ONE 8(3), e58267 (2013).
85. Hauptstock V, Kuriakose S, Schmidt D et al. Glutathione-S-transferase pi 1(GSTP1) gene silencing in prostate cancer cells is reversed by the histone deacetylase inhibitor depsipeptide. Biochem. Biophys. Res. Commun. 412(4), 606-611 (2011).
86. Glazer RI, Knode MC, Tseng CK, Haines DR, Marquez VE. 3-Deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells. Biochem. Pharmacol. 35(24), 4523-4527 (1986).
87. Tan J, Yang X, Zhuang L et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21(9), 1050-1063 (2007).
88. Miranda TB, Cortez CC, Yoo CB et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8(6), 1579-1588 (2009).
89. Shiota M, Takeuchi A, Yokomizo A, Kashiwagi E, Tatsugami K, Naito S. Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth. J. Urol. 188(1), 300-306 (2012).